All news (page 100)

• 

  6 November 2025

  Boehringer Ingelheim's Apecotrep Reduces Proteinuria in Phase II Kidney Trial

  Apecotrep, a TRPC6 inhibitor, showed 40% proteinuria reduction in FSGS patients. Phase III trial recruiting; further Phase II trials planned for other kidney diseases.
• 

  6 November 2025

  Air Products Fiscal 2025 Results Summary

  Fiscal 2025 saw adjusted EPS of $12.03, with a $2.9B operating income. Q4 adjusted EPS was $3.39. Fiscal 2026 EPS guidance is $12.85-$13.15, with $4B in capital expenditures expected.
• 

  6 November 2025

  Sasol Develops Methane Rich Gas Solution for South Africa's Post-2028 Gas Supply

  Sasol plans to supply Methane Rich Gas from 2028-2030 to bridge South Africa's gas supply gap, pending regulatory approval, while transitioning to LNG for long-term needs.
• 

  6 November 2025

  Perstorp Showcases Sustainable Liquid Cooling at OCP Summit

  PFAS-free, biodegradable liquid cooling solutions are advancing from innovation to adoption, offering safer, efficient, and sustainable options for data centers.
• 

  6 November 2025

  Lhyfe Secures Hydrogen Supply Deal with German Service Station Operator

  Lhyfe will supply 90 tons of RFNBO-certified hydrogen over 15 months to fuel a fleet of buses in Germany, supporting green hydrogen's role in decarbonizing heavy mobility.
• 

  6 November 2025

  Solvay Q3 2025 Financial Results

  Q3 2025 saw a 6.8% sales drop, €232M EBITDA, €117M free cash flow, and €1.7B net debt. 2025 outlook confirmed with €880-930M EBITDA and €300M free cash flow.

• 

  6 November 2025

  PureCycle Technologies Q3 2025 Update

  Record production, expanded product portfolio, and increased sales pipeline. Ironton compounding to boost capacity. Thailand project progresses. €40M EU grant application accepted.
• 

  6 November 2025

  Johnson & Johnson's DARZALEX FASPRO®: First FDA-Approved Treatment for High-Risk Smoldering Multiple Myeloma

  DARZALEX FASPRO® reduces progression risk to active multiple myeloma by 51% in high-risk patients, marking a shift in treatment strategy.
• 

  6 November 2025

  Arkema in Top 100 of Financial Times' 2026 Diversity Leaders

  Arkema improved its diversity ranking, moving from 288th to 94th overall, 15th among French firms, and 3rd in its sector, based on employee surveys and diversity metrics.
• 

  6 November 2025

  Fluor to Monetize Remaining Stake in NuScale

  Fluor will convert Class B units to Class A shares and monetize them by Q2 2026, with agreed restrictions to maintain NuScale's equity value.
• 

  6 November 2025

  Trinseo Q3 2025 Financial Results and Outlook

  Net loss of $110M, negative free cash flow of $38M. Plans to cease virgin MMA in Italy, close polystyrene in Germany, aiming for $30M profitability improvement.
• 

  6 November 2025

  Huntsman Q3 2025 Earnings Report

  Q3 2025 saw a net loss of $25M, adjusted EBITDA of $94M, and free cash flow of $157M. Dividend cut by 65% to $0.35 annually. Restructuring aims for $100M savings by 2026.
• 

  6 November 2025

  Novo Nordisk's CagriSema Reduces Blood Pressure and Inflammation, Lowers Heart Disease Risk

  CagriSema shows potential in reducing blood pressure, inflammation, and heart disease risk, with ongoing trials to assess cardiovascular outcomes.
• 

  6 November 2025

  Novo Nordisk and U.S. Administration to Lower GLP-1 Costs and Expand Access

  Novo Nordisk to lower semaglutide prices in 2026, expand Medicare Part D coverage, and expects a slight negative impact on global sales growth.
• 

  6 November 2025

  Gunvor USA Refinances $2.8 Billion Credit Facility with Expanded Lender Group

  The facility includes $2.11B one-year, $700M two-year tranches, and a $500M accordion. It was oversubscribed, adding four new banks, enhancing liquidity for energy commodities.
• 

  6 November 2025

  Lilly and U.S. Government Expand Access to Obesity Drugs

  Medicare beneficiaries to access obesity drugs at $50/month. LillyDirect offers self-pay options. FDA approval pending.
• 

  6 November 2025

  Lilly Expands Leadership Team for Growth

  Lilly appoints Carole Ho and Adrienne Brown to Executive Committee, expands roles for Daniel Skovronsky and Jacob Van Naarden to drive growth in neuroscience and immunology.
• 

  6 November 2025

  Genmab Reports Q3 2025 Financial Results

  Revenue up 21% to $2.66B. Proposed Merus acquisition. FDA priority review for epcoritamab. Rina-S gets Breakthrough Therapy Designation. Operating profit rose to $1.007B.
• 

  6 November 2025

  OMV and Masdar to Develop 140 MW Green Hydrogen Plant in Austria

  The joint venture will build and operate a major green hydrogen plant in Austria, aiming to decarbonize OMV's refinery and explore future collaborations in synthetic fuels and chemicals.
• 

  6 November 2025

  Lilly's Eloralintide Shows Promising Weight Loss in Phase 2 Obesity Study

  Eloralintide led to significant weight loss and improved cardiometabolic factors in a Phase 2 trial, prompting Phase 3 studies for obesity treatment.
• 

  6 November 2025

  Johnson & Johnson's CAPLYTA® Approved by FDA for Major Depressive Disorder Treatment

  FDA approves CAPLYTA® as adjunctive therapy for major depressive disorder, showing significant symptom improvement and safety in trials, with potential for remission.
• 

  6 November 2025

  ADNOC and Comera Financial Launch Smart Financing for UAE SMEs

  The partnership offers automated purchase order financing to boost SME cash flow, enhance supply chain resilience, and support UAE economic diversification.
• 

  6 November 2025

  EU Progresses on 2030 Climate Goals with Emission Reductions

  The EU cuts emissions by 2.5% in 2024, driven by energy sector efforts. Investments and policies aim to meet 2030 targets, enhance climate resilience, and support global climate action.
• 

  6 November 2025

  Topsoe Partners with NXTClean Fuels for Major U.S. SAF and Renewable Diesel Project

  The project in Oregon will use Topsoe's technologies to produce 50,000 barrels/day of renewable diesel and SAF, aiming for operation by 2029, pending final investment decision.
• 

  6 November 2025

  Clariant and FUHUA Form Joint Venture for Flame Retardants

  The venture will produce halogen-free flame retardants in China, addressing regulatory needs. Clariant expands capacity with a CHF 100M investment and a new production line in Cangzhou.
• 

  6 November 2025

  BASF Beauty Care Solutions Joins UEBT for Ethical Sourcing

  Recognized for eco-conscious supply chains, BASF's Responsibly Active program emphasizes sustainable sourcing, biodiversity, and community empowerment in cosmetic bioactives.
• 

  6 November 2025

  Veolia: Q3 2025 Financial Highlights

  Strong Q3 2025 results: 3.2% revenue growth, 5.4% EBITDA rise, €2.3bn investments, and controlled debt. Confident in meeting annual objectives.
• 

  6 November 2025

  Borealis Marks 15-Year Partnership with Emirates Foundation

  Borealis renews its partnership with Emirates Foundation, investing AED one million to enhance education and social integration in the UAE.
• 

  6 November 2025

  Brenntag Announces Exclusive Distribution Deal with ADM

  The agreement focuses on soy-based ingredients for Eastern Europe, Saudi Arabia, and UAE, enhancing Brenntag's regional reach and ADM's market growth.
• 

  6 November 2025

  Sasol Develops Methane Rich Gas Solution for South Africa's Post-2028 Gas Supply

  Sasol plans to supply Methane Rich Gas from 2028-2030 to bridge the gas supply gap, pending regulatory approval, while transitioning to LNG for long-term needs.